HLS Therapeutics (HLS) investor relations material

Business overview and strategy

• Focuses on specialty pharmaceuticals in North America, targeting neuro/psychiatric and cardiovascular disorders.

• Operates with a model of acquiring US/Canadian rights to commercialize assets.

• Portfolio includes branded and partnered products such as Vascepa, NILEMDO, NEXLIZET, and Clozaril.

• Expanding cardiovascular franchise with new product launches and regulatory filings.

• Pursuing growth through product launches, payer coverage, and business development opportunities.

Financial performance and operations

• Achieved 15% Vascepa revenue growth and 80% cash from operations growth in Q1 2026.

• Adjusted EBITDA grew 78% over two years, excluding royalties.

• Reduced net debt by 52% in two years.

• 2025 revenue projected at $55.5M with $19.6M adjusted EBITDA.

• 2026 revenue guidance of $56-60M, with flat EBITDA due to launch costs.

Product portfolio highlights

• Vascepa and NILEMDO/NEXLIZET are positioned as growth engines in the cardiovascular segment.

• Clozaril provides stable cash flow and holds about 50% branded share in Canada.

• CSAN support network and companion diagnostics enhance Clozaril's value proposition.

• Vascepa demonstrated significant CV event reduction in major trials and continues to grow in prescriptions.

• NILEMDO and NEXLIZET offer oral, non-statin LDL-lowering options, with strong physician awareness and payer progress.